Finanzas de Arbutus Biopharma Corp (ABUS)ABUSArbutus Biopharma Corp

Evaluating the bottom line, Arbutus Biopharma Corp maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -567.16%, while the net margin is -507.20%. These profitability ratios, combined with a Return on Equity (ROE) of 89.58%, provide a clear picture of how effectively ABUS converts its operational activities into shareholder value.

In the context of the broader market, ABUS competes directly with industry leaders such as OBX and SVRA. With a market capitalization of $832.04M, it holds a significant position in the sector. When comparing efficiency, ABUS's gross margin of 100.00% stands against OBX's N/A and SVRA's N/A. Such benchmarking helps identify whether Arbutus Biopharma Corp is trading at a premium or discount relative to its financial performance.

In the latest quarter, Arbutus reported a revenue of $1.01 million, exceeding market expectations, and a net income of $169.7 million in Q1 2026, showcasing a strong recovery after previous losses.